Alcon Inc. - Registered Shares

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Geneva, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alcon Inc. (ALC) CEO David Endicott on Q4 2021 Results - Earning Call Transcript

GENEVA--(BUSINESS WIRE)--Alcon Reports Fourth Quarter and Full Year 2021 Results

Alcon Reports Fourth Quarter and Full Year 2021 Results

Alcon's (ALC) new contact lenses are gaining market share and the Systane brand family has been posting strong double-digit growth in all regions.

Alcon's (ALC) Global Growth Solid, New Lenses Sales Rise

Alcon's (ALC) new preservative-free solution for patients with dry eye symptoms is the latest addition to its leading global artificial tear brand Systane.

Alcon (ALC) Launches Preservative-Free Drops for Dry Eye Relief

GENEVA--(BUSINESS WIRE)--Alcon Announces Launch of Systane Complete Preservative-Free Lubricant Eye Drops in Europe

Alcon Announces Launch of Systane Complete Preservative-Free Lubricant Eye Drops in Europe

GENEVA--(BUSINESS WIRE)--Alcon to Launch DAILIES TOTAL1 Contact Lenses in the U.S. for Patients with Astigmatism

Alcon to Launch DAILIES TOTAL1 Contact Lenses in the U.S. for Patients with Astigmatism

GENEVA--(BUSINESS WIRE)--Alcon Completes Acquisition of Ivantis, Inc., Bringing Hydrus Microstent into Its Global Surgical Portfolio

Alcon Completes Acquisition of Ivantis, Inc., Bringing Hydrus Microstent into Its Global Surgical Portfolio

Alcon (ALC) Vision Care Sales Grow Despite Supply Disruption

Alcon (ALC) enhances contact lens experience, especially for new wearers, with the continued successful rollout of PRECISION1.

Alcon (ALC) on Track With Successful Global PRECISION1 Rollout

GENEVA--(BUSINESS WIRE)--Alcon PRECISION1 Daily Disposable Contact Lenses Now Available in Key Markets Throughout Latin America, Asia & Europe

Alcon Continues Its Successful Rollout of PRECISION1 Daily Disposable Contact Lenses, Now Available in Key Markets Throughout Latin America, Asia & Europe

Segment wise, within Alcon's (ALC) Surgical arm, the portfolio of advanced technology intraocular lenses is driving increased penetration rates of ATIOLs.

Alcon (ALC) Surgical Arm Grows Amid Global Trade Disruption

Alcon (ALC) records year-over-year growth across all sales categories in Surgical and Vision Care in Q3.

Alcon (ALC) Q3 Earnings Beat Estimates, Margin Improves

Novartis

Since being spun off into a separate company in April 2019, Alcon Inc. ( ALC , Financial) shares have thrived while the stock of its former parent, Novartis AG ( NVS , Financial), has languished.

Alcon Big Winner in 2019 Divorce From Novartis

Alcon Inc. (ALC) CEO David Endicott on Q3 2021 Results - Earning Call Transcript

GENEVA--(BUSINESS WIRE)--Alcon Reports Third Quarter 2021 Results

Alcon Reports Third Quarter 2021 Results

FORT WORTH, Texas--(BUSINESS WIRE)--Alcon Unveils Latest Evolution of Cataract Integration and Connectivity at AAO 2021

Alcon Unveils Latest Evolution of Cataract Integration and Connectivity at AAO 2021

GENEVA--(BUSINESS WIRE)--Alcon to Acquire Ivantis, Inc. and its Hydrus Microstent for Surgical Glaucoma, Strengthening Global Ophthalmology Portfolio

Alcon to Acquire Ivantis, Inc. and its Hydrus Microstent for Surgical Glaucoma, Strengthening Global Ophthalmology Portfolio

FORT WORTH, Texas--(BUSINESS WIRE)--Alcon #Academy21 Program to Showcase TOTAL30, Other Innovations that Meet Critical Patient and Practice Needs

Alcon #Academy21 Program to Showcase TOTAL30, Other Innovations that Meet Critical Patient and Practice Needs

GENEVA--(BUSINESS WIRE)--Alcon Celebrates World Sight Day 2021 in Communities Worldwide with Programs for Improved Access to Eye Care

Alcon Celebrates World Sight Day 2021 in Communities Worldwide with Programs for Improved Access to Eye Care

In Presbyopia-correcting Intraocular Lens (PCIOLs), Alcon (ALC) currently leads the market with over 55% of global share and over 80% share in the United States.

Alcon's (ALC) Robust Product Line, Market Rebound Aid Growth

FORT WORTH, Texas--(BUSINESS WIRE)--Alcon Honored with FutureEdge 50 Award

Alcon Honored with FutureEdge 50 Award

Investors continue to be optimistic about Alcon (ALC) backed by robust second-quarter performance and raised 2021 outlook.

Here's Why You Should Add Alcon Stock (ALC) to Your Portfolio

Cooper Companies

National Vision Hlds

EyePoint Pharmaceuticals

Stocks like Alcon (ALC), National Vision (EYE), The Cooper Companies (COO) and EyePoint Pharmaceuticals (EYPT) are gaining momentum amid rising optical care demand.

4 Stocks to Keep a Watch on Amid Growing Optical Care Demand

Alcon Inc. (ALC) CEO David Endicott on Q2 2021 Results - Earnings Call Transcript

Alcon (ALC) records the highest sales in the second quarter of 2021 since its spin-off.

News for Alcon Inc. - Registered Shares Stock (ALC)